Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305387 | 0.92 | MAPT (0.42) | KDM4ENPSR1GAAMAPTMAPK1 | |
| SCHEMBL1304941 | 0.86 | GAA (0.48) | GAAMAPTMAPK1POLBMEN1 | |
| SCHEMBL1305298 | 0.84 | ALDH1A1 (0.40) | KDM4ENPSR1MAPTMAPK1POLB | |
| SCHEMBL1304563 | 0.80 | MAOA (0.39) | KDM4EPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL1304978 | 0.79 | PSEN1 (0.46) | KDM4ENPSR1GAAMAPTMAPK1 | |
| SCHEMBL1305528 | 0.78 | SMN1; SMN2 (0.36) | KDM4ENPSR1POLBMEN1KMT2A | |
| SCHEMBL1305898 | 0.77 | NR1H4 (0.39) | POLBSMN1; SMN2 | |
| SCHEMBL1305269 | 0.77 | CYP1A2 (0.37) | KDM4ENPSR1GAAMAPTPOLB | |
| SCHEMBL9339362 | 0.77 | MAPT (0.56) | GAAMAPTMAPK1MEN1KMT2A | |
| SCHEMBL1306105 | 0.77 | CYP1A2 (0.39) | KDM4ENPSR1GAAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | claimed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | claimed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | claimed |
| US-8053449-B2 | Method for inhibiting AGE complex formation | Cell Viable Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| US-20080076804-A1 | METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION | Cell Viable Corporation | 2008-03-27 | — | — | US | disclosed |
| US-20070099966-A1 | Device and Method for Inhibiting AGE Complex Formation | Cell Viable Corporation | 2007-05-03 | — | — | US | disclosed |
| WO-2007044309-A2 | DEVICE AND METHOD FOR INHIBITING AGE COMPLEX FORMATION | VASIX CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | disclosed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | disclosed |